{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:06:31Z","timestamp":1771891591904,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","award":["G-33-140-1441"],"award-info":[{"award-number":["G-33-140-1441"]}],"id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00467-020-04570-y","type":"journal-article","created":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T23:02:35Z","timestamp":1587942155000},"page":"1445-1453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome"],"prefix":"10.1007","volume":"35","author":[{"given":"Jameela A.","family":"Kari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid A.","family":"Alhasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr S.","family":"Albanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama Y.","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"B\u00f6ckenhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif M.","family":"El-Desoky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"4570_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F (2017) Minimal change disease. Clin.J.Am.Soc.Nephrol. 12:332\u2013345","journal-title":"Clin.J.Am.Soc.Nephrol."},{"key":"4570_CR2","doi-asserted-by":"publisher","unstructured":"Pravitsitthikul N, Willis NS, Hodson EM, Craig JC (2013), Non-corticosteroid immunosuppressive medications for steroid-sensitive nephroticsyndrome in children, Cochrane.Database.Syst.Rev. 29;(10):CD002290- PMID: 24166716 https:\/\/doi.org\/10.1002\/14651858.CD002290.pub4","DOI":"10.1002\/14651858.CD002290.pub4"},{"key":"4570_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0022-3476(78)80032-8","volume":"92","author":"EH Garin","year":"1978","unstructured":"Garin EH, Pryor ND, Fennell RS III, Richard GA (1978) Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy. J Pediatr 92:304\u2013308","journal-title":"J Pediatr"},{"key":"4570_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/jim-2016-000163","volume":"65","author":"HD Fu","year":"2017","unstructured":"Fu HD, Qian GL, Jiang ZY (2017) Comparison of second-line immunosuppressants for childhood refractory nephrotic syndrome: a systematic review and network meta-analysis. J Investig Med 65:65\u201371","journal-title":"J Investig Med"},{"key":"4570_CR5","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2215\/CJN.05691108","volume":"4","author":"HA Kyrieleis","year":"2009","unstructured":"Kyrieleis HA, Lowik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN (2009) Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 4:1593\u20131600","journal-title":"Clin J Am Soc Nephrol"},{"key":"4570_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr.Nephrol. 19:794\u2013797","journal-title":"Pediatr.Nephrol."},{"key":"4570_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12519-014-0453-5","volume":"10","author":"L Sun","year":"2014","unstructured":"Sun L, Xu H, Shen Q, Cao Q, Rao J, Liu HM, Fang XY, Zhou LJ (2014) Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai. World J Pediatr 10:59\u201363","journal-title":"World J Pediatr"},{"key":"4570_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000348470","volume":"181","author":"X Wang","year":"2013","unstructured":"Wang X, Xu H (2013) New insights into treatment of nephrotic syndrome in children. Contrib.Nephrol. 181:119\u2013130","journal-title":"Contrib.Nephrol."},{"key":"4570_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","volume":"121","author":"K Chaiwatanatorn","year":"2003","unstructured":"Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F (2003) Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 121:913\u2013918","journal-title":"Br J Haematol"},{"key":"4570_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","volume":"106","author":"K Dunleavy","year":"2005","unstructured":"Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH (2005) B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106:795\u2013802","journal-title":"Blood"},{"key":"4570_CR11","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822","journal-title":"J Am Soc Nephrol"},{"key":"4570_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.autrev.2012.09.002","volume":"12","author":"AG Kattah","year":"2013","unstructured":"Kattah AG, Fervenza FC, Roccatello D (2013) Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun.Rev. 12:854\u2013859","journal-title":"Autoimmun.Rev."},{"key":"4570_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00467-007-0596-x","volume":"23","author":"J Dotsch","year":"2008","unstructured":"Dotsch J, Muller-Wiefel DE, Kemper MJ (2008) Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible? Pediatr.Nephrol. 23:3\u20137","journal-title":"Pediatr.Nephrol."},{"key":"4570_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","volume":"34","author":"GJ Schwartz","year":"1987","unstructured":"Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am 34:571\u2013590","journal-title":"Pediatr Clin N Am"},{"key":"4570_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s12098-012-0776-y","volume":"79","author":"A Sinha","year":"2012","unstructured":"Sinha A, Bagga A (2012) Nephrotic syndrome. Indian J Pediatr 79:1045\u20131055","journal-title":"Indian J Pediatr"},{"key":"4570_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","volume":"31","author":"H Webb","year":"2016","unstructured":"Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D (2016) Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome. Pediatr.Nephrol. 31:589\u2013594","journal-title":"Pediatr.Nephrol."},{"key":"4570_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00467-018-4133-x","volume":"34","author":"J Hogan","year":"2019","unstructured":"Hogan J, Deschenes G (2019) How to improve response to rituximab treatment in children with steroid-dependent nephrotic syndrome: answer to Drs. Fujinaga and Nishino. Pediatr.Nephrol. 34:361\u2013362","journal-title":"Pediatr.Nephrol."},{"key":"4570_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025\u20131033","journal-title":"Kidney Int"},{"key":"4570_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:1308\u20131315","journal-title":"Clin J Am Soc Nephrol"},{"key":"4570_CR20","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5:2207\u20132212","journal-title":"Clin J Am Soc Nephrol"},{"key":"4570_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281","journal-title":"Lancet"},{"issue":"03\/25","key":"4570_CR22","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13548","volume":"2018","author":"A Bonanni","year":"2018","unstructured":"Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 2018(03\/25):1238\u20131249","journal-title":"Br J Clin Pharmacol"},{"issue":"03\/05","key":"4570_CR23","first-page":"323","volume":"2018","author":"JR Berger","year":"2018","unstructured":"Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB (2018) Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neuro-Oncol 2018(03\/05):323\u2013331","journal-title":"J Neuro-Oncol"},{"key":"4570_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1445-5994.1993.tb01447.x","volume":"23","author":"BD Cleland","year":"1993","unstructured":"Cleland BD, Pokorny CS (1993) Cyclophosphamide related hepatotoxicity. Aust N Z J Med 23:408","journal-title":"Aust N Z J Med"},{"key":"4570_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.12659\/AJCR.889401","volume":"14","author":"SR Subramaniam","year":"2013","unstructured":"Subramaniam SR, Cader RA, Mohd R, Yen KW, Ghafor HA (2013) Low-dose cyclophosphamide-induced acute hepatotoxicity. Am J Case Rep 14:345\u2013349","journal-title":"Am J Case Rep"},{"key":"4570_CR26","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0025-6196(12)60074-3","volume":"68","author":"LS Snyder","year":"1993","unstructured":"Snyder LS, Heigh RI, Anderson ML (1993) Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin Proc 68:1203\u20131204","journal-title":"Mayo Clin Proc"},{"key":"4570_CR27","unstructured":"Haubitz M (2007) Acute and long-term toxicity of cyclophosphamide. Transplantationsmedizin19:S26\u2013S31"},{"issue":"12\/31","key":"4570_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"2014","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DRW (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 2014(12\/31):60\u201365","journal-title":"J Autoimmun"},{"key":"4570_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10157-011-0465-6","volume":"15","author":"T Takei","year":"2011","unstructured":"Takei T, Nitta K (2011) Rituximab and minimal change nephrotic syndrome: a therapeutic option. Clin.Exp.Nephrol. 15:641\u2013647","journal-title":"Clin.Exp.Nephrol."},{"key":"4570_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"2009\/12\/23","author":"AA Prytu\u0625","year":"2010","unstructured":"Prytu\u0625 AA, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K (2010) Rituximab in refractory nephrotic syndrome. Pediatr Nephrol (Berlin, Germany) 2009\/12\/23:461\u2013468","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"4570_CR31","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha IS, Cheong HI, Kim SY, Lee SJ, Kang HG (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine 97:e13157","journal-title":"Medicine"},{"key":"4570_CR32","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u0623 M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G, Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group (2014), Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome, J Am Soc Nephrol 2014\/01\/30: 850\u2013863","DOI":"10.1681\/ASN.2013030251"},{"issue":"06\/23","key":"4570_CR33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/ped.12948","volume":"2016","author":"T Nakagawa","year":"2016","unstructured":"Nakagawa T, Shiratori A, Kawaba Y, Kanda K, Tanaka R (2016) Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome. Pediatr Int 2016(06\/23):1003\u20131008","journal-title":"Pediatr Int"},{"issue":"01\/15","key":"4570_CR34","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"2015","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 2015(01\/15):2259\u20132266","journal-title":"J Am Soc Nephrol"},{"key":"4570_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"2009\/05\/07","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol (Berlin, Germany) 2009\/05\/07:1321\u20131328","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"4570_CR36","doi-asserted-by":"crossref","first-page":"e029232","DOI":"10.1136\/bmjopen-2019-029232","volume":"9","author":"F Scolari","year":"2019","unstructured":"Scolari F, Dallera N, Gesualdo L, Santoro D, Pani A, Santostefano M, Feriozzi S, Mani LY, Boscutti G, Messa P, Magistroni R, Quaglia M, Ponticelli C, Ravani P (2019) Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ Open 9:e029232","journal-title":"BMJ Open"},{"key":"4570_CR37","unstructured":"Chan EY-H, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL-T, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K (2019) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 2020(10\/31):393\u2013401"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-020-04570-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T10:13:52Z","timestamp":1696068832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-020-04570-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4570"],"URL":"https:\/\/doi.org\/10.1007\/s00467-020-04570-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"3 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research ethics committees at both contributing centers approved the study. Written informed consents were obtained from one of the parents of all included children. The study was performed according to the principles of the declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}